PURPOSE: Altered level of S100 calcium-binding proteins is involved in tumor development and progression. However, their role in gastric cancer (GC) is not well documented. We investigated the expression pattern of S100 proteins and differentiation or prognosis as well as possible mechanisms in GC. METHODS: RT-PCR, Western blot analysis, and immunohistochemistry were used to determine the mRNA and protein expression of S100 family genes in GC. The polymorphisms of promoter and 5'-UTR of S100A14 gene were identified and related to luciferase reporter gene activity. Association of S100A14 expression with clinicopathologic features and survival in GC was analyzed. RESULTS: We detected upregulated S100A2, S100A6, S100A10, and S100A11 expression and downregulated S100P and S100B expression in GC. Particularly, we detected differential mRNA and protein expression of S100A14 in GC cell lines and primary tumors. Furthermore, S100A14 expression change was related to a differentiated GC phenotype, with an expression in 31/40 (77.5 %) samples of well-differentiated tumors and 29/85 (34.1 %) samples of poorly differentiated tumors (P < 0.001). Moreover, 5-year survival was better in GC cases with positive than negative S100A14 level (P = 0.02). The genetic variant 425G>A on the 5'-UTR of S100A14 was associated with reduced S100A14 expression in GC cells. CONCLUSION: Decreased expression of S100A14 with presence of its genetic variant 425G>A may be associated with an undifferentiated phenotype and poor prognosis in GC.
PURPOSE: Altered level of S100 calcium-binding proteins is involved in tumor development and progression. However, their role in gastric cancer (GC) is not well documented. We investigated the expression pattern of S100 proteins and differentiation or prognosis as well as possible mechanisms in GC. METHODS: RT-PCR, Western blot analysis, and immunohistochemistry were used to determine the mRNA and protein expression of S100 family genes in GC. The polymorphisms of promoter and 5'-UTR of S100A14 gene were identified and related to luciferase reporter gene activity. Association of S100A14 expression with clinicopathologic features and survival in GC was analyzed. RESULTS: We detected upregulated S100A2, S100A6, S100A10, and S100A11 expression and downregulated S100P and S100B expression in GC. Particularly, we detected differential mRNA and protein expression of S100A14 in GC cell lines and primary tumors. Furthermore, S100A14 expression change was related to a differentiated GC phenotype, with an expression in 31/40 (77.5 %) samples of well-differentiated tumors and 29/85 (34.1 %) samples of poorly differentiated tumors (P < 0.001). Moreover, 5-year survival was better in GC cases with positive than negative S100A14 level (P = 0.02). The genetic variant 425G>A on the 5'-UTR of S100A14 was associated with reduced S100A14 expression in GC cells. CONCLUSION: Decreased expression of S100A14 with presence of its genetic variant 425G>A may be associated with an undifferentiated phenotype and poor prognosis in GC.
Authors: Dipak Sapkota; Ove Bruland; Daniela Elena Costea; Hallvard Haugen; Endre N Vasstrand; Salah O Ibrahim Journal: Eur J Cancer Date: 2010-11-10 Impact factor: 9.162
Authors: M S Al-Moundhri; V Nirmala; I Al-Hadabi; K Al-Mawaly; I Burney; M Al-Nabhani; V Thomas; S S Ganguly; C Grant Journal: J Surg Oncol Date: 2005-09-15 Impact factor: 3.454
Authors: Angela Diamantopoulou; Dimitrios Mantas; Ioannis D Kostakis; George Agrogiannis; Zoe Garoufalia; Nikolaos Kavantzas; Gregory Kouraklis Journal: In Vivo Date: 2020 Jan-Feb Impact factor: 2.155
Authors: Jian Yuan Goh; Min Feng; Wenyu Wang; Gokce Oguz; Siti Maryam J M Yatim; Puay Leng Lee; Yi Bao; Tse Hui Lim; Panpan Wang; Wai Leong Tam; Annette R Kodahl; Maria B Lyng; Suman Sarma; Selena Y Lin; Alexander Lezhava; Yoon Sim Yap; Alvin S T Lim; Dave S B Hoon; Henrik J Ditzel; Soo Chin Lee; Ern Yu Tan; Qiang Yu Journal: Nat Med Date: 2017-09-25 Impact factor: 53.440
Authors: Paula Moravkova; Darina Kohoutova; Stanislav Rejchrt; Jiri Cyrany; Jan Bures Journal: Gastroenterol Res Pract Date: 2016-01-06 Impact factor: 2.260